References
- Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol.52(18), 1502–1517 (2008).
- Plavix [package insert]. Bridgewater, NJ, Sanofi-Aventis US (2008).
- Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol.51(20), 1925–1934 (2008).
- Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360(4), 363–375 (2009).
- Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
- Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet373(9660), 309–317 (2009).
- PPI interactions with clopidogrel revisited. Med. Lett. Drugs Ther.51(1306), 13–14 (2009).
- Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos.32(8), 821–827 (2004).
- Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol. Ther.13(Suppl.) 27–36 (1999).
- Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation119, 2625–2632 (2009).
- Sweeny JM, Gorog DA, and Fuster V. Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements. Nat. Rev. Cardiol.6, 273–282 (2009).
- Ferreiro JL and Angiolillo DJ. Clopidogrel response variability: Current status and future directions. Thromb. Haemost.102, 7–14 (2009).
- Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol.45(8), 1157–1164 (2005).
- Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am. J. Cardiol.98(10A), 4N–10N (2006).
- Jennings LK. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance. Crit. Pathw. Cardiol.8(1), 20–28 (2009).
- Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel. J. Am. Coll. Cardiol.49, 1505–1516 (2007).
- Small DS, Farid NA, Payne CD et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol.48(4), 475–484 (2008).
- Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost.4(11), 2508–2509 (2006).
- Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol.51(3), 256–260 (2008).
- Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J.157(1), 148.e1–5 (2009).
- Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am. J. Cardiol.103(10), 1339–1343 (2009).
- Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost.101, 714–719 (2009).
- Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J. Am. Coll. Cardiol.54(13), 1149–1153 (2009).
- O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis from two randomized trials. N. Engl. J. Med.374(9694), 989–997 (2009).
- Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation111(9), 1153–1159 (2005).
- Roche VF. The chemically elegant proton pump inhibitors. Am. J. Pharm. Educ.70(5), 101 (2006).
- Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes study. Circulation118, S815 (2008).
- Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J. Am. Coll. Cardiol.52(12), 1038–1039 (2008).
- Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ180(7), 1–7 (2009).
- Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA301(9), 937–944 (2009).
- Dunn SP, Macaulay TE, Brennan DM et al. Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation118, S815 (2009).
- Rassen JA, Choudhry NK, Avorn J et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation DOI: 0:CIRCULATIONAHA.109.873497 (2009) (Epub ahead of print).
Websites
- Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine (2007) http://medicine.iupui.edu/flockhart/table.htm
- Stanek EJ, Aubert RE, Flockhart DA et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco outcomes study. Poster Session Presented at: the Society for Cardiovascular Angiography and Interventions. Washington DC May 9 (2009) www.medcoresearch.com/.../SCAI_PPI_Agents_FNL_clinical_brief.pdf
- Bhatt DL, Cryer B, Contant CF et al. The Clopidogrel and the Optimization of GI Events Trial (COGENT) www.cardiosource.com/clinicaltrials/trial.asp?trialID=1872
- US Food and Drug Administration. Center for Drug Evaluation and Research. Early Communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix) Link. (Accessed 2009 October 22)
- European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf (Acccessed October 22 2009)
- The Society for Cardiovascular Angiography and Interventions (SCAI). SCAI statement on “a national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: The Clopidogrel Medco Outcomes Study” www.scai.org/drlt1.aspx?PAGE_ID=5870 (Accessed May 27 2009)
- Prevention of gastrointestinal bleeding in patients with severe ischemic heart disease http://clinicaltrials.gov/ct2/show/NCT00683111?term=Prevention+of+Gastrointestinal+Bleeding+in+Patients+With+Severe+Ischemic+Heart+Disease&rank=1 (Accessed October 22 2009)